Nifty 50
- Apollo Hospitals₹8,027.50361.50 (4.72%)
- BSE₹3,287.20-47.60 (-1.43%)
- ITC₹26611.00 (4.31%)
- Reliance Industries₹1,170.30-7.70 (-0.65%)
- Eicher Motors₹7,050282.50 (4.17%)
- JSW Steel₹1,168-7.20 (-0.61%)
- TCS₹2,15680.00 (3.85%)
- Cipla₹1,301-5.80 (-0.44%)
- HCL Technologies₹1,216.7039.80 (3.38%)
- Adani Ports₹1,76153.00 (3.10%)
- Infosys₹1,023.4026.40 (2.65%)
- Shriram Finance₹940.4523.20 (2.53%)
- Tata Motors PV₹279.906.90 (2.53%)
- UltraTech Cement₹10,675249.00 (2.39%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Piramal Pharma’s UK Facility Gets Seven Observations After US FDA Inspection
Authored By PTI | Last Modified: Sep 15, 2026 10:27 AM IST
Open Free Demat Account
Open Free Demat Account
New Delhi: Piramal Pharma Limited‘s Morpeth facility in the UK has received seven observations after an inspection by the US Food and Drug Administration (US FDA), according to a regulatory filing.
The US FDA conducted the inspection at the facility from September 3-11, 2026, the company said in the filing.
“At the conclusion of the inspection, the USFDA issued a Form-483, with 7 observations. These observations are related to enhancement in our practices, procedures and documentation,” Piramal Pharma stated.
The company said it is addressing these observations and preparing a detailed response for submission to the USFDA within the stipulated timeline.
Piramal Pharma added that it remains committed to maintaining the highest standards of compliance and will work closely with the agency to address all observations comprehensively.
(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)
Disclaimer
At HDFC SKY*, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations.
HDFC SKY from HDFC Securities, one of most trusted trading platforms in India, has been recognized with the *Next-Gen Digi Content Awards 2025-26.
Join Us
Add as preferred source on Google
Open Free Demat Account
Open Free Demat Account
₹197.15
Invest Anytime, Anywhere
By signing up I certify terms, conditions & privacy policy